(Q24244606)

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Cytomegalovirus pp65 antigen-guided preemptive therapy with ganciclovir in solid organ transplant recipients: a prospective, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients. Longitudinal follow-up of CMV pp65 antigenemia assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: a prospective, randomized, controlled, open-label trial1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Immune globulin versus antivirals versus combination for prevention of cytomegalovirus disease in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease after Heart Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Cytomegalovirus (CMV) prophylaxis by acyclovir in pre-transplant CMV-positive renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytom

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Effectiveness of deferred therapy with ganciclovir in renal allograft recipients with cytomegalovirus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

A Trial of Vidarabine for Cytomegalovirus Infection in Renal Transplant Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

7 January 2021

Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

7 January 2021

Controlled trial of prophylactic versus therapeutic use of ganciclovir after liver transplantation in adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

7 January 2021

Failure of ganciclovir prophylaxis to prevent allograft reinfection following orthotopic liver transplantation for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

7 January 2021

Acyclovir in immunocompromised patients with cytomegalovirus disease. A controlled trial at one institution

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

7 January 2021

Polymerase chain reaction-triggered preemptive or deferred therapy to control cytomegalovirus-associated morbidity and costs in renal transplant patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

7 January 2021

Oral ganciclovir in the prevention of cytomegalovirus infection in postkidney transplant "CMV at risk" recipients: a controlled, comparative study of two regimens (750 mg Bid and 500 mg Bid)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

7 January 2021

Effective oral ganciclovir prophylaxis against cytomegalovirus disease in heart transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

7 January 2021

A comparative study of 500 mg BID and 250 mg BID of prophylactic oral ganciclovir in post-kidney transplant "CMV at risk" recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

7 January 2021

Cytomegalovirus immune globulin after liver transplantation: a cost-effectiveness analysis 1

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

7 January 2021

High-dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

7 January 2021

A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal Allografts

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

7 January 2021

Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

7 January 2021

Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

7 January 2021

A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

7 January 2021

Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

7 January 2021

Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

7 January 2021

Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

7 January 2021

The economic impact of cytomegalovirus infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

7 January 2021

CYTOMEGALOVIRUS ANTIGENEMIA DIRECTED PRE-EMPTIVE PROPHYLAXIS WITH ORAL VERSUS I.V. GANCICLOVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN LIVER TRANSPLANT RECIPIENTS1

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

7 January 2021

Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

7 January 2021

High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

7 January 2021

Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005133.PUB2

7 January 2021